Nanomerics Ltd.

Based in the UK, Nanomerics Ltd. , operates as a developer of nano-enabled medicines for eye and CNS disorders. Based in London, the UK and founded in 2010, Nanomerics Ltd. develops innovative therapies utilizing its proprietary technology.

The company focuses on creating targeted drug delivery systems for ophthalmology and central nervous system conditions. The funding will be used to advance its platform and ophthalmology pipeline. Nanomerics specializes in the development of targeted therapies utilizing its proprietary Molecular Envelope Technology (MET) platform, which enhances drug delivery for a range of applications in ophthalmology and central nervous system (CNS) conditions. The MET platform focuses on formulating biocompatible polymer nanoparticles that can effectively package hydrophobic drugs and deliver them directly across biological barriers, including the blood-brain barrier, and to sensitive tissues such as the eye.

Key products include Envelta™, a non-addictive analgesic for nose-to-brain applications, along with several investigational ophthalmic formulations such as OC134, which aims to treat allergic keratoconjunctivitis and various other ocular conditions. The company targets markets predominantly in North America and Europe, where its products are designed for healthcare professionals, hospitals, and research institutions engaged in treating ocular ailments and CNS diseases. Nanomerics generates revenue through strategic partnerships and licensing agreements, particularly for its flagship products like Envelta™ and OC134. The company collaborates with pharmaceutical partners to facilitate the development and commercialization of its therapeutic offerings, leveraging shared expertise and resources.

Revenue transactions primarily occur through B2B relationships, where healthcare providers and pharmaceutical companies procure the advanced drug formulations for clinical use or research purposes. Specific pricing plans for these products are structured based on the partnerships established with clients and the terms agreed upon in licensing agreements, reflecting the value of the proprietary technologies employed in their development. The company plans to advance its platform and ophthalmology pipeline with the recent funding raised in September 2026.